[1]
|
Barman, S., Fatima, I., Singh, A.B., et al. (2021) Pancreatic Cancer and Therapy: Role and Regulation of Cancer Stem Cells. International Journal of Molecular Sciences, 22, 4765. https://doi.org/10.3390/ijms22094765
|
[2]
|
Luu, T. (2021) Epithelial-Mesenchymal Transition and Its Regulation Mechanisms in Pancreatic Cancer. Frontiers in Oncology, 11, Article ID: 646399. https://doi.org/10.3389/fonc.2021.646399
|
[3]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30.
https://doi.org/10.3322/caac.21387
|
[4]
|
Lopez, N.E., Prendergast, C. and Lowy, A.M. (2014) Borderline Resectable Pancreatic Cancer: Definitions and Management. World Journal of Gastroenterology: WJG, 20, 10740-10751. https://doi.org/10.3748/wjg.v20.i31.10740
|
[5]
|
Ortiz, R., Quiñonero, F., Garcia-Pinel, B., et al. (2021) Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. Cancers (Basel), 13, 2058. https://doi.org/10.3390/cancers13092058
|
[6]
|
Inoue, Y., Oba, A., Ono, Y., et al. (2021) Radical Resection for Locally Advanced Pancreatic Cancers in the Era of New Neoadjuvant Therapy-Arterial Resection, Arterial Divestment and Total Pancreatectomy. Cancers (Basel), 13, 1818. https://doi.org/10.3390/cancers13081818
|
[7]
|
Rai, Z.L., Feakins, R., Pallett, L.J., et al. (2021) Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy. Journal of Clinical Medicine, 10, 1609. https://doi.org/10.3390/jcm10081609
|
[8]
|
Kutschat, A., Johnsen, S.A. and Hamdan, F.H. (2021) Store-Operated Calcium Entry: Shaping the Transcriptional and Epigenetic Landscape in Pancreatic Cancer. Cells, 10, 966. https://doi.org/10.3390/cells10050966
|
[9]
|
Arias-Pinilla, G.A. and Modjtahedi, H. (2021) Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers (Basel), 13, 1781. https://doi.org/10.3390/cancers13081781
|
[10]
|
Elsayed, M. and Abdelrahim, M. (2021) The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines, 9, 389.
https://doi.org/10.3390/biomedicines9040389
|
[11]
|
中华人民共和国国家卫生健康委员会. 胰腺癌诊疗规范(2018年版) [J]. 临床肝胆病杂志, 2019, 35(2): 281-293.
|
[12]
|
Russo, S. and Saif, M.W. (2016) 2016 Gastrointestinal Cancers Symposium: Update on Pancreatic Cancer. Annals of Gastroenterology Quarterly Publication of the Hellenic Society of Gastroenterology, 29, 238-240.
https://doi.org/10.20524/aog.2016.0024
|
[13]
|
徐杰. 高强度聚焦超声治疗胰腺癌镇痛疗效体会[J]. 基层医学论坛, 2009(34): 108.
|
[14]
|
Hoy, S.M. (2014) Albumin-Bound Paclitaxel: A Review of Its Use for the First-Line Combination Treatment of Metastatic Pancreatic Cancer. Drugs, 74, 1757-1768. https://doi.org/10.1007/s40265-014-0291-8
|
[15]
|
廖小莉, 廖思娜, 李永强, 黄钰晶, 刘志辉, 黎倩, 黄仕新, 韦军葆. 替吉奥单药治疗老年转移性胰腺癌的疗效观察[J]. 广西医科大学学报, 2018, 35(2): 234-237.
|
[16]
|
刘艳杰, 陆翰杰. 白蛋白结合紫杉醇联合替吉奥治疗晚期胰腺癌的疗效及安全性观察[J]. 中国临床新医学, 2019, 12(9): 997-1000.
|
[17]
|
彭小波, 颜芳, 王斌, 傅强. 白蛋白结合型紫杉醇联合替吉奥治疗吉西他滨治疗失败进展期胰腺癌的临床观察[J]. 中国癌症杂志, 2015, 25(1): 63-66.
|
[18]
|
刘甜, 熊琦, 胡毅. 白蛋白结合型紫杉醇联合替吉奥一线治疗老年晚期胰腺癌患者的临床观察[J]. 现代肿瘤医学, 2018(5): 722-725.
|
[19]
|
庄兴俊, 欧娟娟, 高云姝, 高百春, 顾军. 高强度聚焦超声联合放疗治疗35例胰腺癌的临床分析[J]. 重庆医学, 2010, 39(3): 283-284.
|
[20]
|
Hess, K.R., Varadhachary, G.R., Taylor, S.H., Wei, W., Raber, M.N., Lenzi, R. and Abbruzzese, J.L. (2006) Metastatic Patterns in Adenocarcinoma. Cancer, 106, 1624-1633. https://doi.org/10.1002/cncr.21778
|
[21]
|
Ammori, J.B., Colletti, L.M., Zalupski, M.M., Eckhauser, F.E., Greenson, J.K., Dimick, J., Lawrence, T.S. and McGinn, C.J. (2003) Surgical Resection Following Radiation Therapy with Concurrent Gemcitabine in Patients with Previously Unresectable Adenocarcinoma of the Pancreas. Journal of Gastrointestinal Surgery, 7, 766-772.
https://doi.org/10.1016/S1091-255X(03)00113-6
|
[22]
|
Evans, D.B., Wolff, R.A. and Crane, C.H. (2001) Neoadjuvant Strategies for Pancreatic Cancer.
|
[23]
|
Yoshiya, S., Fukuzawa, K., Inokuchi, S., Kosai-Fujimoto, Y., Sanefuji, K., Iwaki, K., Motohiro, A., Itoh, S., Harada, N. and Ikegami, T. (2019) Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer. Journal of Gastrointestinal Surgery, 24, 1605-1611.
https://doi.org/10.1007/s11605-019-04324-8
|
[24]
|
Powell-Brett, S., Pande, R. and Roberts, K.J. (2021) Achieving “Marginal Gains” to Optimise Outcomes in Resectable Pancreatic Cancer. Cancers (Basel), 13, 1669. https://doi.org/10.3390/cancers13071669
|
[25]
|
Ocuin, L.M., Miller-Ocuin, J.L., Novak, S.M., Bartlett, D.L., Marsh, J.W., Tsung, A., Lee, K.K., Hogg, M.E., Zeh, H.J. and Zureikat, A.H. (2016) Robotic and Open Distal Pancreatectomy with Celiac Axis Resection for Locally Advanced Pancreatic Body Tumors: A Single Institutional Assessment of Perioperative Outcomes and Survival. HPB, 18, 835-842. https://doi.org/10.1016/j.hpb.2016.05.003
|